"The Voice of Oncology in Massachusetts"

Disease Spotlight

_______

Delve into our disease-specific links, providing targeted insights to navigate the intricacies of various oncology and hematology diseases.

B

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

ARTICLE(S):

- Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations

LOCAL EXPERT: Andrew A. Lane, MD, PhD; Physician; Director, Blastic Plasmacytoid Dendritic Cell Neoplasm Center, DFCI; Associate Professor of Medicine, Harvard Medical School

VIDEO(S):

- Dr. Lane on Identification of BPDCN
- Dr. Lane on BPDCN treatment
- Emerging CD123-Targeted Therapies for BPDCN: Pivotal Trial Insights and Future Potential
RESOURCES:
- BPDCN information website
- BPDCN flashcard

Breast Cancer (ER+/HER2- metastatic)

RESOURCES:
- ESR1 mutation information website
- ERS1 testing educational brochure

M

Multiple Myeloma

ARTICLE(S):

- Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article

RESOURCES:

- Myeloma Central for patients & caregivers: www.myelomacentral.com/livingwithmm

- MM Center for Nurses for HCPs: www.mmcenterfornurses.com

- Standing in the Gaap for African American patients & caregivers: www.myelomacentral.com/africanamericans

- Multiple Myeloma Research Foundation

Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

ARTICLE(S):
- Exploring REBLOZYL: A Breakthrough Therapy for Anemia in MDS

RESOURCES:

- Nat ional Cancer Institute information on MDS/MPN
- MDS Foundation

- Anemia in Patients With MDS

S

Systemic Mastocytosis (SM)

Systemic Mastocytosis (SM) is a clonal mast cell neoplasm associated with the uncontrolled proliferation and activation of abnormal mast cells. The World Health Organization (WHO) diagnostic criteria identify types of SM, including Indolent Systemic Mastocytosis (ISM) and Advanced Systemic Mastocytosis (AdvSM). SM is driven by the KIT D816V mutation in 95% of cases. Unpredictable and potentially severe symptoms occur in patients with SM. Read more about SM symptoms here.
It is critical to use high-sensitivity KIT D816V assays, as low-sensitivity assays may fail to detect the mutation. A highly sensitive PCR-based method can be used to screen for the presence of KIT D816V in peripheral blood. Read more about high-sensitivity KIT D816V testing here.
For more information on Systemic Mastocytosis, The Mast Cell Disease Society has additional resources here.
VIDEO(S):